肝衰竭患者血浆置换治疗后血清胆红素和凝血酶原活动度变化规律浅探

doi:10.3969/j.issn.1672-5069.2020.03.021

摘要/Abstract

摘要： 目的研究血浆置换(PE)治疗肝衰竭患者血清胆红素和凝血酶原活动度变化规律。方法 2015年2月～2018年8月安徽医科大学第二附属医院肝病科住院的肝衰竭患者47例,分别接受3次以上PE治疗。采用二元多因素Logistic回归分析影响肝衰竭患者短期预后的因素。结果在治疗12 w末,本组47例患者生存22例(46.8%),死亡25例;25例死亡患者年龄为(47.5±13.4)岁、基线MELD评分为(33.5±6.1)分、PTA为(23.8±10.1)%、APTT为(93.8±40.6)s,与22例生存患者比,差异显著,死亡组肝性脑病发生率为64.0%,显著高于生存组的27.3%(P＜0.05);多因素 Logistic 回归分析提示年龄和基线PTA是影响肝衰竭患者短期预后的独立危险因素;经线性回归分析发现,PE术后TBIL下降与术前TBIL 水平呈正相关(r=0.866,P＜0.05),首次PE术后PTA升高最显著(P＜0.05)。结论年龄和凝血酶原活动度是影响肝衰竭患者预后的独立危险因素,了解这些重要的指标对判断病情和及时地给予处理对改善预后很有帮助。

关键词: 肝衰竭, 血浆置换, 预后 , ,

Abstract: Objective The aim of this study was to investigate the therapeutic efficacy of plasma exchange (PE) in the treatment of patients with liver failure. Methods A total of 47 patients with liver failure were admitted to the Second Affiliated Hospital, Anhui Medical University from February 2015 through August 2018, and all patients underwent three or more PE treatment, and followed-up for 12 weeks. Multivariate Logistic analysis was applied to reveal the impacting factors of survival. Results At the end of 12 weeks, 22 (46.8%)survived, and 25 died; the age, baseline MELD score, PTA and APTT in the fatal group were (47.5±13.4)yr, (33.5±6.1), (23.8±10.1)% and (93.8±40.6)s, significantly different compared to , and the incidence of hepatic encephalopathy in fatal group was 64.0%, significantly higher than 27.3%(P＜0.05) in survivals; multivariate Logistic analysis showed that the age and baseline PTA were the independent factors affecting prognosis of patients with liver failure; the decreased serum bilirubin levels after PE were positively correlated to serum bilirubin levels before(r=0.866, P＜0.05), and the PTA increased most obviously after first PE treatment(P＜0.05). Conclusion Our findings suggest that patients’age and baseline PTA are the independent risk factors for short-term prognosis in patients with liver failure, and the clinicians should take these factors into consideration in clinical practice to deal with in time.

Key words: Liver failure, Plasma exchange, Prognosis

罗凌,邓万玉,彭蕾,张振华,邹桂舟. 肝衰竭患者血浆置换治疗后血清胆红素和凝血酶原活动度变化规律浅探[J]. 实用肝脏病杂志, 2020, 23(3): 384-387.

Luo Ling, Deng Wanyu, Peng Lei, et al.. Preliminary study on therapeutic efficacy of plasma exchange in the treatment of patients with liver failure[J]. Journal of Practical Hepatology, 2020, 23(3): 384-387.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171.
[2] Nishimura A, Umehara Y, Umehara M, et al. Plasma exchange based plasma recycling dialysis system as a potential platform for artificial liver support. Artif Organs, 2006, 30: 629-633.
[3] 李易灿,高春明,张莉,等.人工肝血浆置换对肝衰竭的治疗作用及影响因素分析.中华全科医学,2015,13(12):1947-1949.
[4] Yue-Meng W, Yang LH, Yang JH, et al. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int, 2016, 10(3): 462-469.
[5] Wan YM, Li YH, Xu ZY, et al. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entercavir: a prospective study. J Clin Apher, 2017, 32(6): 453-461.
[6] Laleman W, Claria J, Van der Merwe S, et al. Systemic inflammation and acute-on-chronic liver failure: too much, not enough. Can J Gastroenterol Hepatol, 2018, 2018: 1027152.
[7] Wu C, Zhu Y, Yu M. Serum metabonomics analysis of liver failure treated by nonbioartificial liver support systems. Can J Gastroenterol Hepatol, 2018, 2018: 2586052.
[8] Steadman RH, Van Rensburg A, Kramer DJ. Transplantation for acute liver failure: perioperative management. Curr Opin Organ Transplant, 2010, 15(3): 368-373.
[9] 彭思璐,刘冰,孙宏,等.HBV相关慢加急性肝衰竭患者预后及其影响因素分析.实用肝脏病杂志,2019,22(4):545-548.
[10] Cheng YL, Chang CH, Chen WT, et al. Prognostic factors and treatment effect of standard-volume plasma exchange for acute and acute-on-chronic liver failure: a single-center retrospective study. Transfus Apher Sci, 2018, 57(4): 537-543.
[11] Qin G, Shao JG, Wang B, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine, 2014, 93(28): e338.
[12] Riordan SM. Acute liver failure: targeted artificial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure. J Hepatol, 2000, 32(1 Suppl): 63-67.
[13] Gu J, Shi X, Ren H, et al. Systematic review: extracorporeal bio-artificial liver-support system for liver failure. Hepatol Int, 2012, 6(4): 670-683.
[14] Chen JJ, Huang JR, Yang Q, et al. Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China. Hepatobiliary Pancreat Dis Int, 2016, 15(3): 275-281.
[15] Sanz N, Diez-Fernandez C, Alvarez AM, et al. Age-related changes on parameters of experimentally-induced liver injury and regeneration. Toxicol Appl Pharmacol, 1999, 154(1): 40-49.
[16] Yuen MF, Sablon E, Hui CK, et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis, 2003, 36(8): 979-984.
[17] 王威,吴霞,颜炳柱,等.血浆置换治疗68例肝衰竭的临床疗效观察.实用肝脏病杂志,2010,13(2):134-136.
[18] Mao WL, Chen Y, Chen YM. Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange. J Clin Gastroenterol, 2011, 45(6): 551-555.
[19] Gerth HU, Pohlen M, Pavenstdt H, et al. Extracorporeal liver support of liver failure. Z Gastroenterol, 2017, 55(4): 383-393.
[20] Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher, 2019, 34(4): 392-398.